Introduction
Caveolin-1 (CAV1) is a structural component of caveolae and involved in diverse cellular functions such as vesicular transport, cholesterol homeostasis and signal transduction (1) . Despite a growing body of evidence on CAV1 implication in tumorigenesis, its role in cancer development and progression is still contentious. Both tumor suppression and promotion roles of CAV1 have been proposed on the basis of its expression levels detected in cancers. CAV1 expression is reduced in many human cancers and also down-regulated in cells transformed by oncogenes, such as v-Abl, Bcr-
Abl, and H-Ras
G12V (1, 2) . Moreover, CAV1 null mice are more susceptible to carcinogen-induced skin tumor formation and a mutation in CAV1 has been identified in 16% of scirrhous breast carcinoma, leading to the proposal that CAV1 may function as a tumor suppressor (3, 4) . Nevertheless, accumulating evidence argues that CAV1 has tumor-promoting functions. CAV1 is increased in several cancers, including prostate and breast carcinomas, and its elevation is associated with enhanced tumor progression, multidrug resistance, and metastatic activity (5, 6) . However, the molecular basis for its oncogenic effects remained largely undefined.
Cancer cells often take up high amounts of glucose and rely on glycolysis rather than mitochondrial respiration for ATP generation despite the presence of oxygen, a phenomenon known as the Warburg effect (7) . This metabolic shift toward aerobic glycolysis enables cancer cells to convert glucose more efficiently into macromolecules which are needed for rapid cell growth. Glucose is a hydrophilic molecule which can not enter the cell by simple diffusion and thus expression of specific facilitative transporters, named as GLUT is commonly elevated in cancer cells. GLUT3, one of the 14 members of the SLC2 family of GLUTs, is highly expressed in various cancer cells including colon carcinoma (8, 9) . Previous studies showed that CAV1 is associated with glucose metabolism (10-12). It was also reported that insulin receptors are localized in caveolae microdomains and the structure of caveolae is important in glucose uptake (11) .
Furthermore, a recent study revealed that down-regulation of CAV1 in stromal fibroblasts undergo aerobic glycolysis and generate high levels of glycolytic end products, and promote adjacent cancer cell growth by the paracrine secretion of these energy-rich glycolytic bioproducts (12) .
AMPK is a cellular energy sensor that is activated by an increasing cellular AMP:ATP ratio caused by metabolic stresses that interfere with ATP production or that accelerate ATP consumption (13) . AMPK activation turns on catabolic pathways that generate ATP while turning off ATP-consuming pathways. Given its role as metabolic sensor and modulator, AMPK has been implicated as the initiator of cell-cycle arrest under low-glucose conditions and a connection to cell-cycle regulators. Consistently, AMPK acts as an upstream activator of p53 and this AMPK-p53 signaling plays an important role in metabolic changes during cancer development (14) . It was also shown that p53 transactivates SESTRIN1 and SESTRIN2, resulting in AMPK phosphorylation, which subsequently inhibits mTORC1 activity leading to growth arrest and autophagy (15) . These findings thus suggest that tumor cells lacking a functional AMPK or p53 continue to proliferate under energetically stressful conditions.
We report here that overexpressed CAV1 in colorectal cancer cells enhances aerobic glycolysis through the HMGA1-mediated GLUT3 transcription. We found that CAV1 depletion down-regulates glucose uptake and ATP production and causes autophagy via activation of AMPK-p53 signaling. Therefore, our data suggest that performed using the Molecular Analyst software program (Bio-Rad, Hercules, CA 
Reporter constructs and luciferase assay
Human GLUT3 promoter regions were cloned into the pGL3-basic vector (Promega, TGCCAG-3' and 5'-AGCCTG-3' for GATA3; 5'-GGCCCG-3' for SP1) using sitedirected mutagenesis. Cells were transfected with 500 ng of the promoter constructs using Lipofectamine 2000 (Invitrogen). Luciferase activity was measured by using
Immunoprecipitation was performed with HMGA1 antibody (Santa Cruz Biotechnology). PCR was performed using the following primer pairs: GLUT3-P2 (5'-CTGATTTTCTTCTCTCAGGCTGTC-3') and GLUT3-P3 (5'-CCATACAAAACGAAGTCAAGTGG-3').
Measurement of intracellular ATP and lactate levels and glucose uptake
Intracellular ATP levels were measured using ATP bioluminescence assay kit HSII (Roche Applied Science). Briefly, 6 x 10 5 cells were lysed with boiling lysis reagent and supernatant was collected. Fifty μl of diluted sample were mixed with 50 μl of luciferin/luciferase reagents. Luminescence was measured using Luminoskan Ascent 
Statistical analysis
Student t-test was used to determine the statistical significance of the difference.
The χ2 test was used to determine the statistical significance of expression and methylation status between tumor and normal tissues. P-value of less than 0.05 was considered significant. Pearson's correlation coefficient (r) was used to measure the strength of the association between CAV1, GLUT3, and HMGA1 expression levels.
Research. 
Results

Oncogenic conversion of CAV1 function in colorectal cancers
To explore CAV1 role for colorectal tumorigenesis, we initially characterized its expression status in 19 cancer cell lines and 100 primary tumors. CAV1 expression was detected in all cell lines and tissues but its levels were highly variable among specimens (Fig. 1A) . CAV1 mRNA levels in normal tissues, primary tumors and cell lines were observed in a range of 0.60-1.64 (mean 1.12), 0.04-2.93 (mean 1.01), and 0.03-3.09 (mean 1.08), respectively (Fig. 1B) . However, 30 (30%) and 15 (15%) of 100 primary tumors expressed CAV1 mRNA less than a half (< 0.56) and more than 2-folds (> 2. 24) of normal means (1.12), respectively. Compared to adjacent noncancerous tissues, 37 (37%) and 26 (26%) cancerous tissues displayed substantially low and high expression, respectively, indicating that CAV1 expression is down-or up-regulated in colorectal cancers ( Supplementary Fig. S1A ). Both α and β transcripts of CAV1 and CAV2 showed comparable expression while CAV3 transcript was not detected (data not shown). 
CAV1 depletion induces autophagy by activation of AMPK-p53 signaling
Research. To further define the growth-promoting role of CAV1, we examined its effect on cell metabolism using HCT116 cells. Interestingly, microscopic analyses revealed that CAV1 knockdown increases autophagic phenotypes, including formation of autophagosome ( Fig. 2A and B) . CAV1 depletion increased several autophagy markers (LC3-II, ATG5/12, and P-ULK) and expression of autophagy-related genes, such as Beclin-1, DRAM, SESTRIN1, and TIGAR ( Fig. 2C and D) . Consistently, expression of p70S6K, a target of mTOR that inhibits autophagy, was down-regulated by CAV1 blockade ( observed that P-Akt and P-p38 levels are increased by CAV1 depletion while P-Erk1/2, P-JNK, and P-IκB levels are not affected ( Supplementary Fig. S2F ).
p53 mediates CAV1 depletion-induced autophagy and growth suppression
Next we characterized role for p53 in autophagy induction. As predicted, p53 stability was markedly increased in CAV1-depleted cells ( Supplementary Fig. S3A ).
While phosphorylation at serine 15 and 37 was elevated, serine 46 phosphorylation, which is known to activate apoptotic signaling of p53, was not affected by CAV1 blockade (Supplementary Fig. S3B ). Consistently, p21
Waf1 expression was increased by CAV1 depletion, but proapoptotic targets of p53, such as NOXA, PUMA and BAX, showed no response ( Supplementary Fig. S3C ). On this basis, we compared CAV1 effect on tumor cells harboring different p53 status. While AMPK activation by CAV1
knockdown was detected in all tumor cells we tested, autophagy induction was recognized only in wtp53-carrying cells (Fig. 3A) . Moreover, CAV1 depletion led to autophagy and related gene expressions in HCT116 p53 +/+ cells but not in p53 -/-subline cells, indicating a p53-dependent induction of autophagy ( Fig. 3B and C) . Consistently, both in vitro cellular growth and in vivo xenograft tumor growth were more significantly attenuated by CAV1 depletion in p53 +/+ cells versus p53 -/-cells ( Fig. 3D-F ).
CAV1 up-regulates glucose uptake and aerobic glycolysis by GLUT3 induction
AMPK activation by CAV1 depletion suggests that CAV1 might be involved in ATP metabolism. We observed that CAV1 depletion significantly decreases intracellular ATP level in high CAV1-expressing colon (HCT116 and LoVo) and gastric (MKN1) cancer cells ( Fig. 4A and Supplementary Fig. S4A ). Cancer cells prefer to utilize glycolysis to produce ATP despite the presence of oxygene (7). Thus, we tested whether CAV1 affects glucose uptake and aerobic glycolysis. In all three cell lines, glucose uptake and lactate accumulation were substantially decreased by si-CAV1 transfection ( Fig. 4B and Supplementary Fig. S4B ). As predicted, an addition of non-metabolic glucose analog (2-DG) led to AMPK activation and autophagy induction in HCT116 cells, indicating that ATP production and cell growth are highly relied upon aerobic glycolysis ( Supplementary Fig. S4C ). We tested whether CAV1 induction of aerobic glycolysis is
Research. Fig. S4D and E). These show that elevated CAV1 up-regulates ATP production by enhancing both aerobic glycolysis and mitochondrial respiration.
Next we examined whether CAV1 affects expression of glucose transporters. Among 14 GLUT genes (GLUT1-14) we examined, only GLUT3 showed a substantial reduction of its mRNA level in CAV1-depleted cells (Fig. 4C) . GLUT3 was also found to partially co-localize with CAV1 and its level was markedly reduced in CAV1-depleted cells ( Fig.   4D and Supplementary Fig. S4F) . While GLUT4 mRNA level was slightly decreased by CAV1 depletion, expression of other 12 GLUT genes was barely detectable or not affected by CAV1 in colon cancer cells we tested ( Supplementary Fig. S4G ). GLUT3 reduction by CAV1 depletion was observed in both p53 +/+ and p53 -/-cells, indicating that CAV1 induction GLUT3 occurs in p53-independent fashion (Supplementary Fig.   S4H ). Knockdown of GLUT3 expression led to a marked reduction of cellular growth, which is comparable to si-CAV1-induced growth inhibition ( Supplementary Fig. S4I ).
Moreover, consistent with si-CAV1's effect, si-GLUT3 evoked growth inhibition effect more significantly in p53 +/+ cells compared with p53 -/-cells (75% versus 36% reduction). As predicted, GLUT3 depletion resulted in a marked decrease in glucose uptake and intracellular ATP level, AMPK activation and autophagy induction ( Fig. 4E and F).
CAV1 enhances HMGA1-mediated GLUT3 gene transcription
We investigated whether CAV1 affects GLUT3 transcription using promoter reporter assays (Fig. 5A ). Compared to empty luciferase vector, the P1007-Luc and P515-Luc
reporters, which comprise nucleotides +1 to -1007 and +1 to -515, led to more than 20-22 fold increase in luciferase activity, but this increase was greatly attenuated in CAV1-depleted cells (Fig. 5B) . While P515-Luc activity was reduced by si-CAV1, the activity of the P258-Luc and P188-Luc reporters was not influenced by CAV1 depletion (Supplementary Fig. S5A ). This indicates that the sequence region between -515 and -288, which contains the putative binding sites for HMGA1, GATA3 and Sp1, plays a critical role for the response to CAV1. Using reporters containing mutated binding sites, we found that the HMGA1-binding site (HMGA1-BS1; -435 to -420) but not GATA3-or Sp1-binding sites was required for CAV1 activation of the promoter (Fig. 5B and data not shown). The MT1-P515-Luc reporter containing a mutated HMGA1-BS1 was unable to respond to CAV1 depletion while the MT2-P515-Luc reporter containing a mutated HMGA1-BS2 (-138 to -117) showed CAV1 responsiveness, indicating that HMGA1-BS1 plays a critical role in CAV1 activation of GLUT3 transcription (Fig. 5B) .
The GLUT3 chromatin was specifically immunoprecipitated with antibody against HMGA1, but this interaction was greatly attenuated from CAV1-depleted cells (Fig. 5C ).
Moreover, HMGA1 depletion decreased GLUT3 mRNA expression, glucose uptake and intracellular ATP level while it activated AMPK-p53 signaling ( Fig. 5D and Supplementary Fig. S5B ). To understand the mechanism underlying CAV1 induction of HMGA1-mediated GLUT3 transcription, we tested whether CAV1 binds to HMGA1, but failed to detect an interaction between two proteins (data not shown). Expression of HMGA1 and its phosphorylation and acetylation were also not affected by CAV1 depletion (Fig. 5E) . It has been known that activity of HMGA1 as a transcription factor is controlled primarily by its intracellular distribution (18, 19) . Thus, we analyzed CAV1 effect on the subcellular distribution of HMGA1. Interestingly, the nuclear HMGA1 was 
reduced and its cytoplasmic level was concomitantly increased following si-CAV1 transfection (Fig. 5F ). This finding suggests that CAV1 may up-regulate HMGA1 binding to the GLUT3 promoter by enhancing its nuclear localization (Fig. 5F ).
CAV1 cooperates with HMGA1 to activate GLUT3 expression
We assessed whether GLUT3 expression is related to CAV1 or HMGA1 level in colon cancers. In 19 cancer cell lines, GLUT3 level was strongly correlated with CAV1 level (r = 0.739; P < 0.01) and HMGA1 level (r = 0.62; P < 0.01) (Fig. 6A and B) .
Given that HMGA1 expression is not up-regulated by CAV1, it is conceivable that high GLUT3 expression could be achieved when CAV1 and HMGA1 are simultaneously elevated in the same cells. As predicted, SNU-C2A cells with high CAV1 but low HMGA1 level and RKO cells with high HMGA1 but low CAV1 level exhibited low GLUT3 expression (Fig. 6A) . To test this possibility, we compared GLUT3-inducing activity of HMGA1 under high and low CAV1 conditions. In high CAV1-expressing LoVo cells, WT-HMGA1 transfection activated GLUT3 expression but, this effect was diminished by si-CAV1 co-transfection (Fig. 6C) . Likewise, although WT-CAV1 transfection exerted no detectable effect on GLUT3 expression in SW480 cells, GLUT3-inducing activity of HMGA1 was greatly enhanced by WT-CAV1 co-transfection (Fig.   6D ). Consistently, HMGA1 binding to the GLUT3 chromatin was greatly increased when SW480 cells were co-transfected with WT-CAV1 and WT-HMGA1 ( Supplementary Fig. S6A ). We next evaluated the relationship between CAV1, HMGA1 and GLUT3 in 20 matched tissue sets, which have markedly lower or higher CAV1 in cancer tissues compared to its adjacent normal tissues. CAV1 protein levels were comparable to its mRNA levels and showed a tight correlation with GLUT3 levels ( tumors while none of 10 low CAV1 tumors showed GLUT3 elevation (Fig. 6F) .
Moreover, all of the 8 high GLUT3 tumors but none of 12 low GLUT3 tumors exhibited high HMGA1 (Fig. 6E) 
Discussion
We demonstrate here that elevated CAV1 in colorectal cancer cells enhances aerobic glycolysis by up-regulating glucose uptake through HMGA1-mediated GLUT3 induction. Our data also suggest that elevated expression of CAV1 may protect cancer cells from metabolic stresses and thus contribute to tumor progression through the regulation of glucose metabolism.
The regulation of CAV1 expression and its biological significance in colorectal tumorigenesis have been poorly defined (20) . In this study, we found that a substantial of tumor cells that do not express CAV1 (24) . We found that elevated CAV1 in colorectal cancer cells is implicated in enhanced glucose uptake and aerobic glycolysis.
Our data show that CAV1 up-regulates glucose uptake, lactate accumulation and intracellular ATP level. CAV1 regulation of ATP generation was also supported by activation of AMPK, which directly senses increases in the intracellular AMP:ATP ratio, by its depletion. These results indicate that elevated CAV1 enhances aerobic glycolysis.
Aerobic glycolysis is an inefficient way to produce ATP compared with mitochondrial respiration. Nevertheless, most of cancer cells from diverse origin have a high rate of glycolysis. Moreover, it was shown that the upregulation of glycolytic metabolism correlates with increased tumor aggressiveness and poor patient prognosis (25) . It was proposed that the glycolytic shift is beneficial for rapidly proliferating cancer cells that require macromolecules such as nucleotides, amino acids, and lipids (26) . It was also proposed that cancer cells prefer glycolysis for ATP generation because active mitochondrial respiration may generate exaggerated levels of ROS, which may have detrimental effects on tumor growth (27) . We observed that both mitochondrial membrane potential and intracellular ROS level are decreased in CAV1-depleted cells, suggesting that elevated CAV1 in cancer cells may increase both aerobic glycolysis and mitochondrial respiration. The role for CAVs in glucose metabolism has been suggested by several studies (10, 11) . Interestingly, recent studies demonstrated that stromal fibroblasts lacking CAV1 undergo aerobic glycolysis and generate high levels of glycolytic end products, and promote tumor growth by the paracrine secretion of these energy-rich glycolytic bioproducts (12) . Furthermore, it was suggested that cancer cells uses oxidative stress to induce CAV1 downregulation in adjacent fibroblasts via a lysosomal-mediated pathway and that aerobic glycolysis in stromal cells is a direct consequence of autophagy promoted by loss of CAV1 (27) . This finding is in line with our results from epithelial
tumor cells, suggesting that CAV1 effect on glycolysis and autophagy may not be a cell type-specific.
HMGA1 is a member of non-histone DNA-binding proteins, which contain three DNA binding domains and an acidic carboxy-terminal region (17) . HMGA1 is involved in diverse cellular processes, including embryonic development and neoplastic transformation and tumor progression. Although HMGA1 has no intrinsic transcriptional activity, it regulates gene transcription by altering chromatin structure via protein-DNA and protein-protein interactions (18) . We found that HMGA1 is a transcription factor for GLUT3 and CAV1 induces GLUT3 expression by up-regulating HMGA1 interaction with GLUT3 promoter. HMGA1 blockade attenuated glucose uptake and activated AMPK signaling, supporting its implication in glucose metabolism.
Furthermore, HMGA1 binging to the GLUT3 promoter, GLUT3 expression and glucose uptake were increased in low CAV1 cells by co-transfection of CAV1 and HMGA1 but not by CAV1 alone. It was reported that CAV1 is also localized in the nucleus and can bind to promoter of genes, such as cyclin D1 (29). In this study, we could not detect CAV1 binding to the GLUT3 promoter. To elucidate molecular basis for CAV1 regulation of HMGA1, we carried out a series of assay, but failed to detect its interaction with or post-translational modification of HMGA1. Interestingly, however, it was observed that nuclear amount of HMGA1 is enhanced by CAV1, raising the possibility that CAV1 increases HMGA1 activity as a transcription factor by enhancing its nuclear localization. Further studies are needed to elicit the underlying mechanism for CAV1 regulation of HMGA1.
In conclusion, CAV1 elevation is found in many primary colorectal carcinomas and cell lines and implicated in increased aerobic glycolysis. High CAV1 up-regulates 
glucose uptake through HMGA1-mediated GLUT3 transcription and its depletion results in autophagy by AMPK-p53 signaling. Collectively, our study suggests that elevated CAV1 expression may contribute to colorectal tumor progression by rendering tumor cells growth and survival advantages by enhancing glycolysis and ATP generation.
